Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Biotech
BioAge secures Novartis deal worth up to $550M biobucks
The Novartis deal comes less than two weeks after BioAge discarded a phase 2 obesity trial and less than three months after its Nasdaq debut.
Gabrielle Masson
Dec 18, 2024 10:44am
BioAge obesity study derailed by side effects 2 months after IPO
Dec 9, 2024 4:36am
What can we learn from 2024’s biotech IPOs?
Dec 6, 2024 8:44am
HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial
Nov 25, 2024 9:20am
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
Septerna goes public with upsized offering of $288M
Oct 25, 2024 10:29am
